Breaking News

Statement by US Secretary of Labor Walsh on November Jobs Report B-21 Raider makes public debut; will become backbone of Air Force’s bomber fleet > Air Force > Article Display Africa-U.S.: Commercial Ties will Shape the Partnership in the 21st Century Readout of Secretary Raimondo’s Meeting with Mexican Secretary of Economy Raquel Buenrostro Readout of Secretary Raimondo’s Meeting with French Minister of the Economy, Finance, and Industrial and Digital Sovereignty Bruno Le Maire US Department of Labor finds Family Dollar Stores again exposing workers to fire, entrapment, struck-by hazards, this time at Richmond Hill location The 91st Annual California State Capitol Tree Lighting Ceremony Heightened Financing, Women and Youth Participation Vital for Peace Efforts, Speakers Tell Economic and Social Council, Peacebuilding Commission

Issued: London, UK

GlaxoSmithKline plc (GSK) which has the marketing rights for Lovaza (omega-3-acid ethyl esters) in the US and Puerto Rico, confirmed that U.S. District Judge Sue Lewis Robinson, the presiding judge in the U.S. District Court for the District of Delaware, ruled in Pronova’s favour in Pronova’s patent litigation involving U.S. Patent Nos. 5,656,667 (“’667 patent”) and 5,502,077 (“’077” patent) covering Lovaza.  

The Court found Pronova’s patent claims are valid and would be infringed by Teva Pharmaceuticals USA, Inc. (“Teva”) and Par Pharmaceutical Inc. (“Par”).  

The Lovaza patents are owned by Pronova and licensed to GSK in the United States and Puerto Rico, and cover compositions and methods of using omega-3 fatty acids. The ‘667 patent expires in April 2017 and the ‘077 patent expires in March 2013. Pronova, via its wholly-owned subsidiary Pronova BioPharma Norge AS, filed the patents infringement lawsuit against Teva and Par in April 2009.

Previously, Pronova had entered into an agreement in March 2011 with Apotex Corp. and Apotex Inc. (collectively “Apotex”), to settle their patent litigation in the United States related to Lovaza.  The settlement grants Apotex a license to enter the US market with a generic version of Lovaza in the first quarter of 2015, or earlier depending on certain circumstances.

In 2011, GSK reported Lovaza turnover of £569 million ($916 million).  All GSK sales of Lovaza were generated in the US and Puerto Rico. 

One of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit 

GlaxoSmithKline Enquiries:

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502



Stephen Rea

+44 (0) 20 8047 5502



Sarah Spencer

+44 (0) 20 8047 5502



David Daley

+44 (0) 20 8047 5502






US Media enquiries:

Bernadette King

+ 1 215 751 3632



Karen Collins

+ 1 919 483 2527

(North Carolina)



Analyst/Investor enquiries:

Sally Ferguson

+44 (0) 20 8047 5543



Tom Curry

+ 1 215 751 5419



Gary Davies

+ 44 (0) 20 8047 5503



Jeff McLaughlin

+ 1 215 751 7002



Ziba Shamsi

+ 44 (0) 20 8047 3289


GlaxoSmithKline cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK’ s operations are described under ‘Risk factors’ in the ‘Financial review & risk’ section in the company’s Annual Report 2011 included as exhibit 15.2 to the company’s Annual Report on Form 20-F for 2011.

Source link